By Nicholas G. Miller

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer.

The study met its primary endpoint, with the drug combination demonstrating a statistically-significant and clinically-meaningful improvement in radiographic progression-free survival.

The study also showed a strong trend toward improved overall survival, Pfizer said.

The company also reported benefits in overall response rate and duration of response.

"These unprecedented results demonstrate the potential to deliver benefit earlier in the disease course," said Pfizer Chief Oncology Officer Jeff Legos.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

March 19, 2026 07:41 ET (11:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.